MedTech and In Vitro Diagnostic Co-operatives

Following the announcement made by the Minister for Public Health and Innovation at NHS Expo earlier this year, a competition for NIHR Medtech and In vitro diagnostic Co-operative (NIHR MIC) funding is underway. 

The scheme aims to provide NIHR research infrastructure funding for NHS Organisations to act as centres of expertise for the development of medical technologies and/or the generation of high-quality evidence on commercially-supplied IVDs.  

It is envisaged that the NIHR MICs will be designated and funded to:

  • catalyse NHS “pull” to develop new concepts, demonstrate proof of principle and devise research protocols for new medical devices, healthcare technologies or technology-dependent interventions that are applicable across the NHS. This will address clinical areas or themes of high morbidity and unmet need for NHS patients and healthcare technology users, which have not benefited from a high degree of innovation, including paediatrics which is being highlighted as being of particular strategic importance.

OR

  • catalyse the generation of evidence on commercially-supplied IVDs that is required by the NHS, industry and a range of users including accredited providers of NHS pathology services and NICE. This will focus on clinical areas or themes where evidence of the clinical validity, clinical utility, cost-effectiveness and care pathway benefits of IVDs has the potential to lead to improvements in healthcare services and the quality of life of NHS patients.

OR 

  • address a combination of these two aspects. 

Funding of around £14m will be invested over a five-year period from 1 January 2018 depending on receipt of suitable quality applications.

The closing date for submission of a full application was 25 January 2017 at 13:00. 

The FAQ document that supported the Full Application Guidance is available here.

Any questions should be submitted to Stephanie Guest (stephanie.guest@nihr.ac.uk) at NIHR CCF. 

 

The Independent Selection Panel Members are as follows:

Professor Tom Walley (Chair)

Head of the Institute of Psychology Health and Society and Professor of Health Services Research at University of Liverpool

John Jeans (Deputy Chair)

Chairman of Imanova and Edinburgh Molecular Imaging, and a non- executive Director of Renishaw plc and ProMetic Pharmaceuticals Ltd.

Martin Hunt

Director of the NIHR’s Invention for Innovation (i4i) research programme

Chris Hudson

Director of Healthcare Development and Strategic Services at Roche Diagnostics and member of BIVDA Executive Committee

Dr Sameer Mistry

Medical Director, UK & Ireland, Johnson and Johnson Medical Devices. Chair of the Clinical Directors Forum at the Association of British Healthcare Industries (ABHI).

Barbara Fallowfield

Commercial Manager, Mologic Ltd

Carla Deakin

Associate Director – NICE Office for Market Access

Professor Manuel Salto-Tellez

Professor and Chair of Molecular Pathology; Clinical Director, Molecular Diagnostics; Deputy Director, Centre for Cancer Research and Cell Biology

Professor Tim Peters

Professor of Primary Care Health Services Research and Head of School (SOCS) , University of Bristol

Professor Simon Herrington

Consultant Pathologist, Department of Pathology, Royal Infirmary of Edinburgh

Professor Tony Young

National Clinical Lead for Innovation NHS England

Professor Timo Jämsä

Professor in Medical Technology, University of Oulu

Professor Patricia Connolly

Director of Strathclyde Institute of Medical Devices (SIMD) and CEO of Ohmedics

Professor Catherine Sackley

Chair in Rehabilitation & Head of Physiotherapy, King’s College London

Philip Hurst

PPI panel member